View More Recent Stories

Mar 2, 2022 06:30AM Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference
Feb 3, 2022 06:36AM Nuvalent Inc (NUVL) Appoints Emily Drabant Conley to its Board
Feb 3, 2022 06:30AM Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors
Jan 7, 2022 06:30AM Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor
Jan 4, 2022 06:30AM Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference
Nov 10, 2021 06:30AM Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results
Oct 7, 2021 09:24AM Nuvalent Inc (NUVL) Announces New Data Supporting Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC
Oct 7, 2021 09:21AM New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC
Sep 8, 2021 06:30AM Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
View More Recent Stories